US · CLSD
Clearside Biomedical, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Alpharetta, GA 30005
- Website
- clearsidebio.com
Price · as of 2024-12-31
—
Market cap 21.3M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $17.51 | — |
| Intrinsic Value(DCF) | $7,974.56 | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $476.16 | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | $110.25 | ||||
| 2017 | $195.00 | $137.28 | $0.00 | $0.00 | $839.09 |
| 2018 | $19.50 | $8.58 | $0.00 | $0.00 | $3,205.18 |
| 2019 | $45.30 | $1,225.78 | $326,148.29 | $0.00 | $0.00 |
| 2020 | $45.75 | $238.38 | $32,302,152.42 | $0.00 | $0.00 |
| 2021 | $28.87 | $142.38 | $546,259,799.13 | $10.22 | $26.11 |
| 2022 | $16.20 | $2,672.18 | $969.14 | $0.00 | $683.89 |
| 2023 | $25.05 | $62.58 | $62,400.66 | $0.00 | $0.00 |
| 2024 | $13.92 | $17.51 | $0.00 | $0.00 | $476.16 |
AI valuation
Our deep-learning model estimates Clearside Biomedical, Inc.'s (CLSD) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $17.51
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$7,974.56
— upside
Graham-Dodd
—
— upside
Graham Formula
$476.16
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CLSD | Clearside Biomedical, Inc… | $4.07 | 21.3M | +330% | +195,835% | — | +11,599% | -1.99 | -1.76 | 41.15 | -4.15 | — | -1.76 | 91.05% | -1735.70% | -2064.42% | 125.45% | 701.36% | -116.16% | -1.35 | -2.95 | 4.44 | 4.28 | 0.79 | -1132.00% | -7977.00% | 2894.00% | -37.50% | -5.15 | 623.48% | 0.00% | 0.00% | 48.77% | -3.49 | -3.93 | 60.65 | -22.09 |
| ALLR | Allarity Therapeutics, In… | $1.22 | 17.83M | — | — | — | — | -0.07 | 0.14 | — | 0.68 | — | 0.14 | 0.00% | — | — | -541.17% | 671.53% | -142.07% | 0.11 | -41.72 | 2.06 | 2.01 | 0.75 | -9974.00% | — | 3849.00% | -1036.16% | -1.60 | 441.86% | 0.00% | 0.00% | 1339.49% | 0.60 | 0.93 | — | -10.62 |
| CASI | CASI Pharmaceuticals, Inc… | $1.35 | 20.92M | +796% | -35% | — | +1,224% | -0.86 | 18.23 | 1.18 | -1.14 | -3.22 | 20.92 | 39.06% | -138.84% | -137.57% | -301.80% | -351.62% | -60.89% | 11.96 | -45.49 | 1.09 | 0.86 | -0.25 | 2673.00% | -1577.00% | 3267.00% | -87.31% | -0.80 | -261.48% | 2.13% | -1.80% | 2.13% | -1.00 | -1.35 | 1.39 | -19.70 |
| CING | Cingulate Inc. | $3.82 | 20.68M | — | — | — | — | -0.95 | 1.97 | — | -0.51 | — | 1.97 | 0.00% | — | — | -5305.02% | 1019.77% | -169.38% | 0.68 | — | 2.55 | 2.46 | 0.48 | -9673.00% | — | 2231.00% | -126.84% | -3.71 | 1216.50% | 0.00% | 0.00% | 71.84% | -0.49 | -0.41 | — | -11.88 |
| ENTO | Entero Therapeutics, Inc. | $4.22 | 20.11M | — | — | — | — | -0.43 | 0.13 | — | -491.36 | — | 0.14 | 0.00% | — | — | -58.82% | -0.05% | -39.13% | 0.00 | — | 3.03 | 0.01 | 1.47 | -8880.00% | — | -2842.00% | -119.84% | -0.33 | -31.51% | 0.00% | 0.00% | 0.00% | -490.90 | -0.83 | — | -2.37 |
| LEXX | Lexaria Bioscience Corp. | $1.08 | 21.17M | +2,546% | -61% | — | — | -1.57 | 6.26 | 26.52 | -1.43 | -3.89 | 6.98 | 83.20% | -1647.97% | -1686.00% | -216.06% | -846.18% | -182.65% | 0.04 | — | 2.32 | 1.56 | 0.14 | 4043.00% | 5205.00% | 10942.00% | -55.96% | -7.00 | -761.93% | 0.00% | 0.00% | 0.00% | -1.45 | -1.61 | 23.88 | -22.60 |
| LSTA | Lisata Therapeutics, Inc. | $2.34 | 20.49M | — | -45% | — | — | -0.98 | 0.66 | 19.66 | 0.52 | — | 0.67 | 100.00% | -2240.90% | -1998.50% | -51.43% | 1147.42% | -44.56% | 0.00 | — | 6.16 | 5.73 | 0.72 | -698.00% | — | -337.00% | -98.47% | -3.45 | 1030.67% | 0.00% | 0.00% | 0.00% | 0.51 | 0.59 | -11.45 | -20.94 |
| MTVA | MetaVia Inc. | $1.00 | 24.2M | — | — | — | — | -0.44 | 1.52 | — | 0.13 | -0.97 | 1.52 | 0.00% | — | — | -224.18% | 426.89% | -141.35% | 0.02 | — | 1.94 | 1.94 | 0.55 | 4472.00% | — | 12784.00% | -205.58% | -2.99 | 366.27% | 0.00% | 0.00% | 0.00% | 0.13 | 0.16 | — | -16.10 |
| PALI | Palisade Bio, Inc. | $1.68 | 15.33M | +46% | — | — | — | -0.08 | 0.16 | — | 0.59 | — | 0.16 | 0.00% | — | — | -153.55% | 1021.24% | -115.82% | 0.02 | -1238.25 | 3.24 | 3.04 | 0.67 | -6227.00% | -10000.00% | 948.00% | -1013.04% | -3.77 | 838.01% | 0.00% | 0.00% | 0.00% | 0.57 | 0.69 | — | -20.99 |
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
- CEO
- George M. Lasezkay Pharm.D., Pharma.D.
- Employees
- 32
- Beta
- 1.79
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($7,974.56 ÷ —) − 1 = — (DCF, example).